Anti-Xa inhibitors (e.g., rivaroxaban [Xarelto], apixaban [Eliquis]) are commonly prescribed anticoagulants. Their indications include (but are not limited to) reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation; treating deep venous thromboembolism and pulmonary embolism; and deep venous thromboembolism prophylaxis. Bleeding is a common complication from anti-Xa inhibitor use that may require reversal with andexanet alfa, prothrombin complex concentrate, or plasma. Although the international normalized ration (INR) is commonly used to measure the anticoagulation effect of vitamin K antagonists (e.g., warfarin), it is insensitive for anti-Xa inhibitors, potentially leading to inappropriate patient management decisions.